Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M5,043Revenue $M--Net Margin (%)--Altman Z-Score
Enterprise Value $M5,038EPS $--Operating Margin %--Piotroski F-Score--
P/E(ttm)--Beneish M-Score--Pre-tax Margin (%)--Higher ROA y-yN
Price/Book--10-y EBITDA Growth Rate %--Quick Ratio--Cash flow > EarningsN
Price/Sales--5-y EBITDA Growth Rate %--Current Ratio--Lower Leverage y-yN
Price/Free Cash Flow--y-y EBITDA Growth Rate %ROA % (ttm)--Higher Current Ratio y-yN
Dividend Yield %2.1PEG1.2ROE % (ttm)--Less Shares Outstanding y-yN
Payout Ratio %--Shares Outstanding M--ROIC % (ttm)--Gross Margin Increase y-yN

Gurus Latest Trades with XLV

Number of guru portfolios checked: 68.
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
XLVLeon Cooperman 2015-03-31 Buy 0.42%$67.86 - $74.9
($71.15)
$ 74.395%New holding366,000
XLVKen Fisher 2015-03-31 Add$68.05 - $74.9
($71.32)
$ 74.394%Add 4.15%257,614
XLVKen Fisher 2014-06-30 Add0.01%$55.71 - $61.23
($58.7)
$ 74.3927%Add 34.36%226,412
XLVGeorge Soros 2012-09-30 Sold Out -0.03%$37.27 - $40.3
($38.73)
$ 74.3992%Sold Out0
XLVGeorge Soros 2012-06-30 Buy 0.03%$35.52 - $37.87
($36.91)
$ 74.39102%New holding50,000
XLVKen Fisher 2012-06-30 Add$35.52 - $37.87
($36.91)
$ 74.39102%Add 53.52%119,754
XLVKen Fisher 2011-06-30 Buy 0.01%$33.28 - $36.42
($34.99)
$ 74.39113%New holding86,997
XLVGeorge Soros 2011-03-31 Sold Out $31.5 - $33.18
($32.33)
$ 74.39130%Sold Out0
XLVGeorge Soros 2010-12-31 Reduce-0.15%$30.19 - $31.78
($31.13)
$ 74.39139%Reduce 93.88%34,153
XLVGeorge Soros 2010-09-30 Buy 0.25%$28.03 - $30.68
($29.2)
$ 74.39155%New holding558,053
XLVGeorge Soros 2010-06-30 Sold Out $28.38 - $32.31
($30.13)
$ 74.39147%Sold Out0
XLVGeorge Soros 2010-03-31 Reduce$30.68 - $33
($31.72)
$ 74.39135%Reduce 43.59%6,600
XLVGeorge Soros 2009-12-31 Buy 0.01%$28.07 - $31.62
($30.04)
$ 74.39148%New holding11,700
XLVBill Gates 2009-06-30 Sold Out -4.19%$23.76 - $26.53
($25.04)
$ 74.39197%Sold Out0
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

XLV is held by these investors:

Premium Most recent portfolio changes are included for Premium Members only!


XLV: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
TAYLOR, DAVID ROYDirector, Director or Senior Officer of 10% Securi 2015-06-29Buy3,200$5.451266.24view
Fatt, William RobertDirector 2015-06-29Buy3,100$64.3315.75view
CLULOW, KURT STEFAN VICTORDirector 2015-06-29Buy114,750$2.13445.71view
Sutherland, DerekSenior Officer 2015-06-29Buy21,732$0.174360view
Bigue, StephaneDirector 2015-06-29Sell1,000$0.7310100view
KAINE, MATTHEWSenior Officer 2015-06-29Sell3,500$0.7310100view
PAWLOWICZ, KARLDirector 2015-06-29Sell7,000$0.7310100view
Seemann, HaraldDirector 2015-06-29Sell26,700$0.5413688.89view
Diener, GeraldSenior Officer 2015-06-29Buy100$1.544735.06view
Diener, GeraldSenior Officer 2015-06-29Buy19,900$1.554703.87view

Quarterly/Annual Reports about XLV:

    News about XLV:

    Articles On GuruFocus.com
    S&P 500 Sector ETFs: A Look Under the Hood, Part 3 Mar 11 2015 
    Build a “Whatever Happens” Portfolio – Now! Aug 15 2014 
    Are Earnings Important? These Days, Revenues Count for More! Mar 17 2014 

    More From Other Websites
    Extreme form of tuberculosis enters US Jun 09 2015
    Don’t Forget This Healthcare ETF Jun 08 2015
    Bear Market: Will A Diversified Mix Of ETFs Or Mutual Funds Save You? Jun 06 2015
    Investor Outlook: Focus on Dividend Growth Jun 05 2015
    Evolent Health: Reduced costs, healthier patients Jun 05 2015
    Shallow market pullback preserves the bull trend Jun 02 2015
    A period of sustained growth: Bristol-Myers Squibb CEO Jun 01 2015
    ASCO targets immunotherapy and drug costs Jun 01 2015
    Trading: What's hot, what's not in 2015 Jun 01 2015
    Healthcare, Yen And Oil ETFs To Watch This Week May 31 2015
    The Week Ahead: A Summer Swoon or a Buying Opportunity? May 29 2015
    There's a lot to be happy about: Market pro May 29 2015
    How a Rate Hike Could Affect High-Leverage Sectors May 29 2015
    Dollar’s Impact on Earnings Was Not as Bad as Expected May 28 2015
    Why Head Of Research At A $2.4 Trillion Titan Believes Investors Should Watch These Numbers May 28 2015
    Believe it: Big Healthcare ETF is Ready to Keep Partying May 28 2015
    Is The Strong Dollar A Showstopper For Stock Bulls? May 27 2015
    Tailwinds for US Equities Today May 27 2015
    The Synageva BioPharma–Alexion Deal Spread Has Some Hair on It May 27 2015
    The real issue with Greece May 27 2015

    Add Notes, Comments

    If you want to ask a question, or report a bug, please create a support ticket.

    User Comments

    No comment yet
    Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
    GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
    FEEDBACK